Skerritt J H, Johnston G A
Eur J Pharmacol. 1983 May 6;89(3-4):193-8. doi: 10.1016/0014-2999(83)90494-6.
Several benzodiazepines (chlordiazepoxide, clonazepam, diazepam, midazolam, nitrazepam and oxazepam) produced a concentration-dependent enhancement of low affinity GABA binding to fresh, washed brain membranes in 50 mM Tris-citrate buffer at concentrations comparable to those displacing [3H]diazepam binding in vitro. The nonbenzodiazepine anxiolytics CL218872 and zopiclone also enhanced GABA binding, while the centrally inactive benzodiazepine Ro5-4864 failed to alter GABA binding. The benzodiazepine antagonist, Ro15-1788 did not alter GABA binding but potently antagonised stimulation of GABA binding by 100 nM diazepam. These pharmacological characteristics suggest that an enhancement of the binding of GABA to low affinity receptor sites may give rise to many of the in vivo actions of the benzodiazepines.
几种苯二氮䓬类药物(氯氮卓、氯硝西泮、地西泮、咪达唑仑、硝西泮和奥沙西泮)在50 mM柠檬酸三钠缓冲液中,以与体外取代[3H]地西泮结合的浓度相当的浓度,对新鲜洗涤的脑膜上低亲和力GABA结合产生浓度依赖性增强作用。非苯二氮䓬类抗焦虑药CL218872和佐匹克隆也增强了GABA结合,而中枢无活性的苯二氮䓬类药物Ro5-4864未能改变GABA结合。苯二氮䓬类拮抗剂Ro15-1788未改变GABA结合,但能有效拮抗100 nM地西泮对GABA结合的刺激作用。这些药理学特性表明,GABA与低亲和力受体位点结合的增强可能导致苯二氮䓬类药物的许多体内作用。